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Abstract
Background Several studies have assessed the association
between IL-17F and IL-10 promoter polymorphisms and
asthma, but the results were conflicting. Furthermore, few
studies have evaluated the association of cytokine poly-
morphisms with asthma and its clinical phenotypes.
Objective This study was conducted to evaluate the
association of IL-10 (interleukin 10) and IL-17F (interleukin
17F) promoter polymorphisms (rs1800871, rs1800896 and
rs1889570) with asthma and its clinical phenotypes includ-
ing severity, atopic status, spirometric parameters, and
response to treatment in south Indian population. A sub-
study was conducted to assess cytokine levels in subjects
with different gene variants.
Methods IL-10 and IL-17F polymorphisms were geno-
typed in 419 asthmatic patients and 393 controls using
Mass ARRAY.
Results Our results showed an association between IL-10
SNPs and mild asthma. No association was found with any
of three SNPs in moderate to severe asthma. Comparison of
genotype distribution of IL-17F rs1887570 AA variant
among atopic and non-atopic patients showed significant
difference (p = 0.024). Correlation analysis of IL-10 and
IL-17F SNPs to clinical variables showed a positive cor-
relation between IL-17F rs1887570 AA and number of
allergen sensitized (rs = 0.142, p = 0.004). Significant
improvement in lung function was observed after 2 months
of ICS (Inhaled corticosteroids) and LABA (long acting b2
agonist) treatment in all subjects with no statistically sig-
nificant difference among SNPs variants. Cytokines levels
were similar in different SNP variants.
Conclusion We observed an association between IL-10
rs1800871 and rs1800896 SNPs and mild asthma, as well
as IL-17F rs1887570 AA variant and number of allergens
sensitized.
Keywords Asthma  IL-10  IL-17F  Single nucleotide
polymorphism  Promoter  Atopic status
Introduction
Asthma is the most heterogeneous respiratory disease with
a growing prevalence in resource-rich and resource-poor
countries. It is associated with airway hyper-responsive-
ness, reversible airway obstruction, and allergen-specific
IgE production [1, 2]. Growing body of evidence suggests
the role of genetics in etiology of asthma through interac-
tions with environmental factors [3]. More than 100 genes
have been associated with asthma in candidate gene stud-
ies, positional cloning, or linkage studies [4].
IL-10 was first identified in 1989 as cytokine synthesis
inhibitory factor with a down-regulatory effect on inflam-
matory responses. The IL-10 gene is located on chromo-
some 1 both in human (1q31-32) and murine genomes and
is consisted of 5 exons and 4 introns [5]. It inhibits the
production of several cytokines, chemokines, chemokine
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receptors, and inflammatory enzymes [6]. IL-10 has a
protective role in asthma. While, low levels of IL-10 have
been associated with asthma [7, 8], overexpression of IL-10
in regulatory T cells can suppress airway hyper-respon-
siveness [9].
IL-17F is located on chromosome 6p, a region which is
associated with asthma in several genome studies. Fur-
thermore, gene expression studies have identified IL-17F as
a novel candidate gene in asthma-related studies [10, 11].
The gene-encoding human IL-17F is 7742 bps in length,
consisting of three exons and two introns. It is expressed in
basophils and activated mast cells, mononuclear cells, T
cells clones, and CD4? cells, a group of cells which are
involved in the pathogenesis of asthma [12, 13]. IL-17F is
overexpressed in the asthmatic patients airways where the
level of overexpression is correlated with the severity of
the disease [14]. In asthmatic patients, the overexpression
of IL-17F induces airway neutrophilia, pulmonary mucus
hyper-secretion, and goblet cell hyperplasia [7].
As cytokine expression is genetically controlled at
transcription level, polymorphism in promoter region can
affect cytokine expression level by changing the binding
site of the transcription factors. As IL-10 -1082A/G
polymorphism is located within a negative putative ETS
(E26 transformation-specific or E-twenty-six) -like tran-
scription factor binding site and the -819C/T polymor-
phism is located within a putative positive regulatory
region, these polymorphisms are considered as significant
loci to investigate for their association with asthma which
is affected by the expression level of this cytokine [15].
Several studies have shown the association between these
polymorphisms and asthma [16, 17]. An association
between IL-10 -1082G allele and asthma has been indi-
cated in East Asian population including that of north India
[17, 18]. Although the role of IL-17F overexpression in
asthma and its severity has been established well, very few
studies have investigated the association of this cytokine
polymorphism with asthma, with none from India. Among
the identified IL-17F promoter polymorphisms, rs1889570
polymorphism has shown the highest minor allele fre-
quency in European Americans (MAF: 0.348), African
Americans (MAF: 0.375), and East Asians (MAF: 0.362)
[19, 20].
Although several studies have investigated the associa-
tion between IL-10 and IL-17F polymorphisms and asthma,
very few ones have evaluated the association of these
polymorphisms with asthma clinical phenotypes. Further-
more, population diversities are noticeable and specific
genetic markers exist for each population. This study was
conducted to evaluate the association of IL-10 (rs1800871,
rs1800896) and IL-17F (rs1889570) promoter polymor-
phisms with asthma and its clinical phenotypes including
severity (GINA), atopic status, spirometric parameters, and
response to treatment with ICS and LABA in south Indian
population for the first time. A sub-study was conducted to
assess these cytokine levels in subjects with different IL-10
and IL-17F variants.
Methods
Subjects
This study included 419 asthmatic patients and 393 non-
asthmatic controls. While the asthmatic subjects were
recruited from ‘‘Allergy, Asthma and Chest Center,’’ India,
age and gender-matched controls were selected from the
general population. We included controls who had no
history of asthma or other respiratory diseases, were non-
smokers, and showed normal lung function in Pulmonary
Function Test (PFT).
Spirometry to verify asthma in patients was performed
according to ATS (American Thoracic Society) standards
[21]. Diagnosis of asthma and its severity was performed
according to the current Global Initiative for Asthma
(GINA) guidelines. Asthmatic patients were classified into
three groups: mild persistent, moderate persistent, and
severe persistent [22]. This study was approved by the
ethical committee of the University of Mysore, with
Institutional Human Ethical Committee numbered IHEC-
UOM No.80 PhD/2012-13, and accordingly informed
written consent was obtained from all subjects.
DNA Extraction and SNP Genotyping
Two milliliter of venous blood was collected from the
participants and stored in EDTA tubes at -20 C for fur-
ther analysis. DNA was extracted using Promega Wizard
genomic DNA purification kit. The test procedure was
conducted according to the manufacturer’s guidelines.
Three promoter polymorphisms [IL-10 -819C/T
(rs1800871), IL-10 -1082A/G (rs1800896) and IL-17F
-1507G/A (rs1889570)] were selected for genotyping
using Mass ARRAY technique (eTable 1 in Electronic
Supplementary Material).
Comparison of Serum Cytokine Levels in Subjects
with Different IL-10 and IL-17F SNPs
Serum levels of IL-10 and IL-17F were assessed in 44
asthmatic and 44 non-asthmatic subjects [23]. Commercial
ELISA kits (Ray Biotech Inc., USA) were used to measure
serum levels of IL-10 and IL-17F. The test procedure was
performed according to the manufacturer’s guidelines. IL-
10 and IL-17F serum levels were compared among subjects
with different IL-10 and IL-17F SNPs.
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Association of IL-10 and IL-17F SNPs to Different
Clinical Variables
Total serum IgE was measured using ELFA (Enzyme-
Linked Fluorescent Assay) method (Minividas, France). In
skin prick test (SPT), sensitization to 36 common allergens
(HollisterStier Allergy, USA) was tested where the wheal
size of 3 mm greater than saline control was assumed as
positive [24]. Severity of sensitization was specified by
comparing the largest allergen wheal size with that of
histamine as positive control. Severity of sensitization was
tested according to Aas et al. (1973) where allergen wheal
diameter of greater than histamine is graded as 4? [25].
Comparison of FVC (Forced Vital Capacity)
and FEV1 (Forced Expiratory Volume in 1 s)
Improvements Following Two Months of ICS
and LABA Treatment in Patients with Different
IL-10 and IL-17F SNPs
232 asthmatic patients were followed up after 2 months of
ICS and LABA treatment. The improvement in FVC and
FEV1 was compared among subjects with different IL-10
and IL-17F SNPs. The rest of 187 patients were referred to
their family practitioner and were not available for follow-
up.
Statistical Analysis
Hardy–Weinberg equilibrium (HWE) was calculated using
FINETTI program [26]. The statistical power of the study
was confirmed by Quanto (http://hydra.usc.edu/gxe) soft-
ware V.1.2.4 [27]. Genotype and allelic frequencies were
assessed using Chi-square, Odds Ratio (OR), and 95 %
Confidence Interval (CI). Further analysis was performed
by assessment of genotype frequencies under dominant,
recessive, and additive genetic models [28]. Haplotype–
disease association was assessed using Haploview software
V.4.0 [29]. The association between SNPs and clinical
variables was tested using SPSS software V.19 (SPSS, Inc,
USA). As multiple comparisons were carried out on the
same sample, Bonferroni correction was applied and
P\0.016 was considered as significant.
Results
Demographic characteristics and mean of the spirometric
variables of the study population are presented in Table 1.
IL-10 (rs1800871, rs1800896) and IL-17F (rs1889570)
promoter polymorphisms were genotyped in 419 cases and
393 controls. All the SNPs were in Hardy–Weinberg
equilibrium in both the cases and controls (Table 2). Our
results on power analysis showed the desirable power of
80 % with the relative risk ratio of 1.33 for IL-10
rs1800871 and IL-17F rs1889570 SNPs, and 1.39 for IL-10
rs1800896 SNP. Assessment of genotype and allele dis-
tributions of IL-10 and IL-17F SNPs showed no significant
difference between asthmatics and controls (Table 2). On
subgroup analysis based on asthma severity, IL-10
rs1800871 SNP in both homozygous and heterozygous
conditions as well as allelic distribution and IL-10
rs1800896 SNP in homozygous condition as well as allelic
distribution were significantly different in mild asthmatics
as compared to controls, indicating an association
(Table 3). There was no association with any of three SNPs
in moderate to severe asthma. Comparison of IL-10 and IL-
17F genotypes frequencies between asthmatics and con-
trols under dominant, recessive, and additive genetic
models showed nonsignificant differences (Table 4). On
haplotype analysis, our results showed no significant dif-
ference in IL-10 haplotypes frequencies in asthmatics as
compared to controls (eTable 2 in Electronic Supplemen-
tary Material). The association of IL-10 and IL-17F SNPs
to their serum levels showed no significant difference in
cytokine serum levels in subjects with different IL-10 and
IL-17F SNPs (eTable 3 in Electronic Supplementary
Material). Comparison of genotype distribution of IL-17F
rs1887570 AA variant among atopic and non-atopic
patients showed a significant difference (p = 0.024,
eTable 4 in Electronic Supplementary Material). Compar-
ison of the number of allergens sensitized among atopic
patients with different IL-17F rs1887570 genotypes
showed a significant difference (p = 0.008, eFig. 1 in
Electronic Supplementary Material). The least (47 patients)
and the most (247 patients) amount of sensitization was
shown to helminthosporium and house dust mite mixed
allergens, respectively. Correlation analysis of SNPs to
different clinical variables showed a significant correlation
between IL-17F rs1889570 SNP and the number of aller-
gens sensitized (Table 5, rs = 0.142, p = 0.004). Signifi-
cant improvement in lung function was observed after
2 months of ICS and LABA treatment with no statistically
significant difference between SNPs variants (Table 6).
Discussion
One of the major goals of SNP studies is to perceive the
genetic basis of human phenotype variation, especially of
complex diseases [30]. Identification of asthma-associated
genetic variants may be clinically useful for identification
of the patients at risk [31]. Our results showed an associ-
ation between IL-10 rs1800871 and rs1800896 SNPs and
mild asthma in south Indian population (Table 3). There
was no association with any of the three SNPs in moderate
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to severe asthma. Comparison of IL-17F rs1887570 AA
genotype distribution among atopic and non-atopic patients
showed significant difference (p = 0.024, eTable 4 in
Electronic Supplementary Material). Comparison of the
number of allergens sensitized among atopic patients with
different IL-17F rs1887570 genotypes showed a significant
difference (p = 0.008, eFig. 1 in Electronic Supplemen-
tary Material). Correlation analysis of IL-10 and IL-17F
SNPs to clinical variables showed a correlation
(rs = 0.142, p = 0.004) between IL-17F SNP and the
number of allergen sensitized (Table 5). No difference was
observed when serum cytokines levels were compared
between subjects with different IL-10 and IL-17F SNPs
(eTable 3 in Electronic Supplementary Material). Signifi-
cant improvement in lung function was observed after
2 months of ICS and LABA treatment with no statistically
significant difference between SNPs variants (Table 6).
Most of the interest in IL-10 has focused on the pro-
moter region to illustrate the variation in IL-10 levels by
altering the binding site of the transcription factors [32].
Our results showed an association between IL-10 rs1800871
and rs1800896 polymorphisms and mild asthma, where a
significant difference was noticed in T and G allele
frequencies in controls than mild asthmatics (Table 3).
No association was found with IL-10 SNPs in moderate
to severe asthma. Several studies have investigated the
association between IL-10 promoter polymorphism and
asthma (eTable 5 in Electronic Supplementary Material),
but the results are inconsistent [17, 18]. While some
have reported the association between IL-10 polymor-
phism and asthma [33, 34], others have reported nega-
tive results [35–37]. Such discrepancies are because of
differences in patient demographics, sample size, envi-
ronmental factors, genetic background, study design,
asthma definition, gene–gene and gene–environment
interactions.
We observed an association of both IL-10 SNPs with
mild asthma, but not with moderate and severe asthma.
This observation should be confirmed in other studies.
Unlike this study, most of the studies on IL-10 SNPs and
Table 1 General characteristics
of the study population
Controls Cases
Age
B40 years 231 (58.8 %) 247 (58.9 %)
[40 years 162 (41.2 %) 172 (41.1 %)
Sex
Male 200 (50.9 %) 213 (50.8 %)
Female 193 (49.1 %) 206 (49.2 %)
Smoking status
Smoker 0 (0 %) 49 (11.7 %)
Non-smoker 393 (100 %) 370 (88.3 %)
Family history of asthma
Yes 0 (0 %) 189 (45.1 %)
No 393 (100 %) 230 (54.9 %)
Severity
Mild persistent – 108 (25.8 %)
Moderate persistent – 170 (40.6 %)
Severe persistent – 141 (33.6 %)
Sensitization level
No sensitization – 40 (9.5 %)
BHistamine – 216 (51.6 %)
[Histamine – 163 (38.9 %)
Mean ± SE of total serum IgE – 668.45 ± 39.21
Pulmonary function test Pre-bronchodilator Pre-bronchodilator
Mean ± SE of FVC [%] 88.35 ± 10.59 69.88 ± 18.93
Mean ± SE of FEV1[%] 88.76 ± 9.84 66.57 ± 20.58
Mean ± SE of FEV1/FVC % 104.18 ± 7.35 97.48 ± 13.77
Mean ± SE of PEF [L/s] 92.66 ± 19.61 71.94 ± 23.13
IgE immunoglobulin E, SE standard error of mean, FVC forced vital capacity, FEV1 forced expiratory
volume in 1 s, PEF peak expiratory flow
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asthma have not assessed the association of IL-10 SNPs
with different subgroups of asthma severity (GINA), pos-
sibly containing a heterogeneous severity groups. Reports
suggest different pathogenesis mechanisms, pathways, and
cytokine profiles in mild as compared to severe asthma
[38]. There is a need for further analysis of our subjects
with different asthma severities to understand the patho-
genetic mechanism of IL-10 in mild asthma.
The -1082 A allele is associated with reduced IL-10
levels, whereas the -1082G allele is associated with ele-
vated IL-10 levels [39]. Lack of association between IL-10
promoter polymorphism and its serum levels (eTable 3 in
Electronic Supplementary Material) may show that these
promoter sites does not affect IL-10 expression, both alleles
are codominantly expressed and there are other genes
which regulate IL-10 expression [40]. The presence of
serum inhibitors, disparate assay sensitivities, ethnic dis-
crepancies in impact of IL-10 polymorphism on its
expression level [41] and possibility of false negatives due
to small sample size are other factors to explain our non-
significant results.
Comparison of the IL-10 SNPs among atopic and non-
atopic patients showed nonsignificant differences (eTable 4
in Electronic Supplementary Material). Our results are in
line with other studies showing no difference between
atopic and non-atopic asthma with respect to IL-10 pro-
moter polymorphisms [35, 37]. Correlation analysis of IL-
10 SNPs to clinical variables showed nonsignificant results
(Table 5). Karjalainen et al. [42] found no association
between IL-10 polymorphism and lung function in asth-
matic patients. As lung function is a complex trait, a couple
of genes may not cause enough variation to change the
spirometric parameters significantly [32].
IL-17F induces the expression of several proinflamma-
tory cytokines, chemokines, and growth factors which are
involved in leukocyte activation and airway remodeling in
patients with asthma [43]. No association was found
between IL-17F promoter polymorphism and asthma in our
study population (Tables 2, 3). Our results are in line with
the results of Kawaguchi et al. [20] who found no associ-
ation between IL-17F rs1889570 polymorphism and
asthma. Overall variation in IL-17F expression cannot be
solely because of the variation in the promoter region.
Polymorphisms in the gene located upstream in the
inflammatory pathway may change IL-17F expression as
opposed to SNPs within IL-17F itself.
Comparison of IL-17F serum level among subjects with
different IL-17F variants showed nonsignificant differences
(eTable 3 in Electronic Supplementary Material) showing
that this promoter polymorphism may not affect the IL-17F
expression or other genes may regulate the expression of
this cytokine [44]. Comparison of IL-17F rs1887570 AA
variant among atopic and non-atopic patients showed a
significant difference (p = 0.024, eTable 4 in Electronic
Table 2 Hardy–Weinberg equilibrium test, genotype, and allelic distributions of IL-10 and IL-17F SNPs in asthmatic patients and healthy
controls
Gene SNP Total no. of
samples
Minor allele
frequency
Genotype Controls Cases OR (95 % CI) P value HWE p value
Controls Cases Controls Cases Controls Cases
IL-10 rs1800871 393 419 0.452 0.437 CC 126 138 1 (referent) – 0.088 0.263
CT 178 195 1.00 (0.73–1.37) 0.998
TT 89 86 0.88 (0.60–1.29) 0.520
C 430 471
T 356 367 0.94 (0.77–1.15) 0.544
IL-10 rs1800896 393 419 0.222 0.241 AA 238 244 1 (referent) – 0.879 0.478
AG 135 148 1.07 (0.80–1.43) 0.655
GG 20 27 1.32 (0.72–2.41) 0.372
A 611 636
G 175 202 1.11 (0.88–1.40) 0.380
IL-17F rs1889570 393 419 0.530 0.508 GG 85 107 1 (referent) – 0.743 0.263
AG 199 198 0.79 (0.56–1.12) 0.183
AA 109 114 0.83 (0.56–1.22) 0.348
G 369 412
A 417 426 0.92 (0.75–1.11) 0.371
SNP single nucleotide polymorphism, OR odds ratio, HWE Hardy–Weinberg equilibrium, IL-10 interleukin 10, IL-17F interleukin 17F
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Table 3 Genotype and allele frequency distributions of IL-10 and IL-17F SNPs among controls (CT) and patients with mild asthma (MI),
moderate asthma (MO), and severe asthma (SE)
Gene SNP Genotype Controls
(n = 393)
Cases
(n = 419)
OR (95 % CI) p value
MI MO SE MI/CT MO/CT SE/CT MI/CT MO/
CT
SE/
CT
IL-10 rs1800871 CC 126 11 43 53 1 (referent) 1 (referent) 1 (referent) – – –
CT 178 42 87 65 2.70
(1.34–5.45)
1.43
(0.93–2.20)
0.87
(0.57–1.33)
0.005 0.102 0.517
TT 89 55 40 23 7.08
(3.51–14.28)
1.32
(0.79–2.19)
0.61
(0.35–1.08)
\0.0001 0.289 0.088
C 430 64 173 171
T 356 152 167 111 2.87
(2.07–3.97)
1.17
(0.90–1.50)
0.78
(0.59–1.03)
\0.0001 0.237 0.085
IL-10 rs1800896 AA 238 54 104 86 1 (referent) 1 (referent) 1 (referent) – – –
AG 135 42 60 46 1.37
(0.87–2.16)
1.02
(0.69–1.49)
0.94
(0.62–1.43)
0.174 0.930 0.781
GG 20 12 6 9 2.64
(1.22–5.74)
0.69
(0.27–1.76)
1.24
(0.55–2.84)
0.013 0.433 0.601
A 611 150 268 218
G 175 66 72 64 1.54
(1.10–2.15)
0.94
(0.69–1.28)
1.03
(0.74–1.42)
0.011 0.685 0.881
IL-17F rs1889570 GG 85 29 47 31 1 (referent) 1 (referent) 1 (referent) – – –
AG 199 48 75 75 0.71
(0.42–1.20)
0.68
(0.44–1.06)
1.03(0.63–1.69) 0.196 0.090 0.895
AA 109 31 48 35 0.83
(0.47–1.49)
0.80
(0.49–1.30)
0.88(0.50–1.54) 0.538 0.364 0.656
G 369 106 169 137
A 417 110 171 145 0.92
(0.68–1.24)
0.90
(0.69–1.16)
0.94
(0.71–1.23)
0.579 0.394 0.637
SNP single nucleotide polymorphism, OR odds ratio, IL-10 interleukin 10, IL-17F interleukin 17F
Table 4 Comparison of
genotype frequencies between
controls and asthmatic cases by
dominant, recessive, and
additive models
Gene SNP Model Genotype Controls Cases OR (95 % CI) p value
IL-10 rs1800871C/T Dominant CC/CT?TT 126/267 138/281 1.04 (0.78–1.40) 0.790
Recessive CC?CT/TT 304/89 333/86 0.88 (0.63–1.23) 0.463
Additive CC 126 138
CT 178 195 1.00 (0.73–1.37)
TT 89 86 0.88 (0.62–1.26) 0.763
IL-10 rs1800896A/G Dominant AA/GA?GG 238/155 244/175 0.91 (0.69–1.20) 0.500
Recessive AA?GA/GG 373/20 392/27 0.78 (0.43–1.41) 0.409
Additive AA 238 244
GA 135 148 1.07 (0.80–1.43)
GG 20 27 1.23 (0.66–2.30) 0.643
IL-17F rs1889570G/A Dominant GG/GA?AA 85/308 107/312 1.17 (0.84–1.63) 0.341
Recessive GG?GA/AA 284/109 305/114 1.03 (0.75–1.40) 0.866
Additive GG 85 107
GA 199 198 0.79 (0.56–1.12)
AA 109 114 1.05 (0.76–1.46) 0.405
SNP single nucleotide polymorphism, OR odds ratio, IL-10 interleukin 10, IL-17F interleukin 17F
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Supplementary Material), where the most number of
allergens sensitized were observed in atopic patients with
IL-17F rs1887570 AA variant. Correlation analysis of IL-
17F rs1889570 variant to clinical variables showed a cor-
relation (rs = 0.142, p = 0.004, Table 5) between IL-17F
SNP and the number of allergen sensitized. Interestingly,
Table 5 Haplotype analysis of
IL-10 rs1800871 and rs1800896
SNPs among asthmatic patients
and healthy controls
Haplotype Haplotype Frequency Case: Control Ratio v2 value p value
TA 0.442 0.437: 0.447 0.161 0.687
CA 0.326 0.322: 0.331 0.133 0.715
CG 0.229 0.240: 0.217 1.268 0.260
v2 chi-square value
Table 6 Mean concentration of IL-10 and IL-17F in different genotypes of the corresponding genes variants
SNP Genotype Controls Cases Mean ± SEM of IL-10
in controls (pg/ml)
Mean ± SEM of IL-
10 in cases (pg/ml)
Mean ± SEM of IL-
17F in controls (pg/ml)
Mean ± SEM of IL-
17F in cases (pg/ml)
rs1800871 CC 10 22 17.20 ± 2.40 3.36 ± 0.59 325.35 ± 60.06 3754.75 ± 796.07
rs1800871 CT 25 16 13.61 ± 2.14 2.63 ± 0.68 195.92 ± 27.17 2634.33 ± 737.79
rs1800871 TT 9 6 16.18 ± 4.95 2.24 ± 1.23 190.79 ± 49.38 5068.06 ± 2390.31
P value 0.200 0.522 0.143 0.525
rs1800896 AA 29 22 15.34 ± 2.10 3.61 ± 0.66 210.77 ± 28.54 3030.18 ± 759.57
rs1800896 AG 13 16 15.23 ± 3.04 2.65 ± 0.56 254.66 ± 48.09 3535.82 ± 908.45
rs1800896 GG 2 6 7.42 ± 0.35 1.28 ± 0.78 222.87 ± 34.24 4667.13 ± 1937.42
P value 0.279 0.204 0.679 0.323
rs1889570 GG 9 11 15.24 ± 4.75 3.31 ± 0.87 272.32 ± 70.23 3321.57 ± 1091.41
rs1889570 AG 19 19 16.82 ± 2.71 2.80 ± 0.63 225.58 ± 37.32 3508.51 ± 903.75
rs1889570 AA 16 14 12.56 ± 1.88 2.83 ± 0.76 195.73 ± 30.63 3711.66 ± 1078.40
P value 0.458 0.830 0.748 0.869
SNP single nucleotide polymorphism, SEM standard error of mean, OR odds ratio, IL-10 interleukin 10, IL17F interleukin 17F, pg/ml pictogram
per milliliter
Table 7 Correlation analysis of IL-10 and IL-17F SNPs to various clinical variables
IL-10 rs1800871 IL-10 rs1800896 IL-17F rs1889570
Asthma duration rs = 0.010, p = 0.844 rs = 0.002, p = 0.975 rs = 0.025, p = 0.614
Smoking status rs = 0.036, p = 0.464 rs = 0.089, p = 0.069 rs = 0.060, p = 0.223
Severity rs = -0.031, p = 0.521 rs = - 0.085, p = 0.084 rs = - 0.025, p = 0.614
Sensitization level rs = 0.007, p = 0.889 rs = - 0.011, p = 0.815 rs = 0.081, p = 0.098
Number of allergens sensitized rs = 0.024, p = 0.629 rs = 0.001, p = 0.980 rs = 0.142, p = 0.004
Total serum IgE rs = 0.050, p = 0.383 rs = 0.022, p = 0.698 rs = - 0.064, p = 0.258
FVC [%] rs = 0.040, p = 0.419 rs = 0.062, p = 0.205 rs = - 0.040, p = 0.411
FEV1[%] rs = 0.017, p = 0.727 rs = 0.076, p = 0.120 rs = - 0.012, p = 0.802
FEV1/FVC % rs = - 0.087, p = 0.074 rs = 0.079, p = 0.105 rs = 0.064, p = 0.192
PEF [L/s] rs = - 0.022, p = 0.657 rs = 0.062, p = 0.178 rs = - 0.023, p = 0.642
Reversibility in FVC rs = 0.073, p = 0.134 rs = 0.076, p = 0.122 rs = 0.019, p = 0.700
Reversibility in FEV1 rs = 0.019, p = 0.692 rs = 0.061, p = 0.215 rs = 0.006, p = 0.900
rs Spearman correlation coefficient. p value of\0.05 is considered as significant
IgE immunoglobulin E, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, PEF peak expiratory flow
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comparison of the number of allergens sensitized among
atopic patients with different IL-17F rs1887570 genotypes
showed a significant difference (p = 0.008, eFig. 1 in
Electronic Supplementary Material). The positive correla-
tion between the number of allergens sensitized and IL-17F
rs1889570 variants suggests the role of IL-17F in atopic
sensitization. IL-17F was first established in BALF of
atopic patients on stimulation with ragweed allergen [13].
Inhaled corticosteroids are the most common medica-
tions to control asthma. It is likely that the response to ICS
treatment has a genetic background [45]. Our results
showed significant improvement in lung function after
2 months of ICS treatment with no statistically significant
difference between SNPs variants (Table 6). Lack of
association between IL-10 and IL-17F SNPs and spiro-
metric parameters can be because of the complex genetic
basis of response to ICS treatment or not including other
functional SNPs which may be associated in our population
(Tables 7, 8).
To the best of our knowledge, this is the first report on
the association of asthma and IL-10 promoter polymor-
phism in south Indian population and on the association of
asthma and IL-17F promoter polymorphism in India.
Taking a desirable sample size, collection of control sam-
ples from the general population and assessment of various
clinical variables are other advantages of this study. Our
study has several potential limitations. Unlike the controls,
the cases of our study were recruited from the hospital and
not from the general population. Some of the subgroup
analysis performed did not have sufficient sample size in
the subgroups.
In conclusion, our results showed an association
between IL-10 SNPs and mild asthma and IL-17F
rs1887570 AA with number of allergens sensitized. Further
large scale investigations along with in vitro functional
experiments are required to assess the potential roles of
these polymorphisms in asthma.
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